OmRx Oncology begins phase 2 trial of oral PD-L1 inhibitor OX-4224 in patients with non-small cell lung cancer: San Diego Saturday, May 10, 2025, 12:00 Hrs [IST] OmRx Oncology, or ...

Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ETCompany ParticipantsJustine Koenigsberg - Vice President ...

BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and ...

The construction work currently underway in Saudi Arabia for the Neom giga-project is unprecedented, with buildings like the ...

Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia Phase Ib/IIa trial is to evaluate the efficacy of VES001 in asymptomatic patients ...

Study will evaluate OX-4224 as a second-line monotherapy in patients with PD-L1–positive non-small cell lung cancer, expanding potential access to checkpoint ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

During the second half of 2025, Werewolf plans to present interim data from the monotherapy and combination expansion arms, including tolerability, response rate, and durability, and to engage with ...

HBO's The Last of Us Season 2 Episode 4 expanded on Ellie and Dina's storyline in Seattle, after they escaped from Jackson to ...

Could Island Pharmaceutical’s ISLA-101 small molecule treatment be an answer to dengue fever? The US DoD is paying close attention.

Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA 1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule ...

With only about $1.6 billion in debt in December 2024 compared with $0.3 billion in cash and investments, Waters maintains a financially flexible balance sheet with net leverage around 1 time. Waters ...